Progress in the Presence of Failure: Updates in Chronic Systolic Heart Failure Management (Q39317320)

11 September 2017

1 reference

title

Progress in the Presence of Failure: Updates in Chronic Systolic Heart Failure Management (English)

1 reference

11 September 2017

0 references

1 reference

systolic heart failure

1 reference

Katie M Murphy

1

1 reference

11 September 2017

Julie L Rosenthal

series ordinal

2

1 reference

11 September 2017

publication date

1 July 2017

1 reference

Current treatment options in cardiovascular medicine

11 September 2017

published in

1 reference

11 September 2017

volume

19

1 reference

11 September 2017

issue

7

1 reference

11 September 2017

page(s)

50

1 reference

The "Modern" View of Heart Failure: How Did We Get Here?

11 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS11936-017-0552-4

2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contrib

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11936-017-0552-4

Wireless pulmonary artery haemodynamic monitoring in chronic heart failure: a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11936-017-0552-4

Heart Disease and Stroke Statistics-2016 Update: A Report From the American Heart Association

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11936-017-0552-4

Angiotensin-neprilysin inhibition versus enalapril in heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11936-017-0552-4

Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11936-017-0552-4

Heart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardiovascular risk: results of the EMPA-REG OUTCOME® trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11936-017-0552-4

Evaluation of the efficacy and safety of RLY5016, a polymeric potassium binder, in a double-blind, placebo-controlled study in patients with chronic heart failure (the PEARL-HF) trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11936-017-0552-4

Effect of Patiromer on Serum Potassium Level in Patients With Hyperkalemia and Diabetic Kidney Disease: The AMETHYST-DN Randomized Clinical Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11936-017-0552-4

Patiromer in patients with kidney disease and hyperkalemia receiving RAAS inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11936-017-0552-4

Effect of sodium zirconium cyclosilicate on potassium lowering for 28 days among outpatients with hyperkalemia: the HARMONIZE randomized clinical trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11936-017-0552-4

Targeting the renin-angiotensin-aldosterone system in heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11936-017-0552-4

Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11936-017-0552-4

Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11936-017-0552-4

Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11936-017-0552-4

A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11936-017-0552-4

The neprilysin pathway in heart failure: a review and guide on the use of sacubitril/valsartan

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11936-017-0552-4

The path to an angiotensin receptor antagonist-neprilysin inhibitor in the treatment of heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11936-017-0552-4

Comparison of vasopeptidase inhibitor, omapatrilat, and lisinopril on exercise tolerance and morbidity in patients with heart failure: IMPRESS randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11936-017-0552-4

Comparison of omapatrilat and enalapril in patients with chronic heart failure: the Omapatrilat Versus Enalapril Randomized Trial of Utility in Reducing Events (OVERTURE).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11936-017-0552-4

Angiotensin receptor neprilysin inhibition compared with enalapril on the risk of clinical progression in surviving patients with heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11936-017-0552-4

ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the [...]

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11936-017-0552-4

Cost-Effectiveness of Sacubitril-Valsartan in Patients With Heart Failure With Reduced Ejection Fraction

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11936-017-0552-4

Predictors of mortality and morbidity in patients with chronic heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11936-017-0552-4

Heart rate as a prognostic risk factor in patients with coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a subgroup analysis of a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11936-017-0552-4

Analysis of randomized controlled trials on the effect of magnitude of heart rate reduction on clinical outcomes in patients with systolic chronic heart failure receiving beta-blockers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11936-017-0552-4

Funny channels in the control of cardiac rhythm and mode of action of selective blockers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11936-017-0552-4

I f inhibition with ivabradine : electrophysiological effects and safety

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11936-017-0552-4

Influence of Cardiovascular and Noncardiovascular Co-morbidities on Outcomes and Treatment Effect of Heart Rate Reduction With Ivabradine in Stable Heart Failure (from the SHIFT Trial).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11936-017-0552-4

Ivabradine in stable coronary artery disease without clinical heart failure.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11936-017-0552-4

Ivabradine for patients with stable coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a randomised, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11936-017-0552-4

Effects on outcomes of heart rate reduction by ivabradine in patients with congestive heart failure: is there an influence of beta-blocker dose?: findings from the SHIFT (Systolic Heart failure treatment with the I(f) inhibitor ivabradine Trial) stu

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11936-017-0552-4

Diabetes and cardiovascular disease. The Framingham study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11936-017-0552-4

Heart failure: the frequent, forgotten, and often fatal complication of diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11936-017-0552-4

Intensive glucose control and macrovascular outcomes in type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11936-017-0552-4

Renal sodium-glucose transport: role in diabetes mellitus and potential clinical implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11936-017-0552-4

Safety, tolerability, pharmacokinetics, and pharmacodynamics of multiple rising doses of empagliflozin in patients with type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11936-017-0552-4

CONSENSUS STATEMENT BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY ON THE COMPREHENSIVE TYPE 2 DIABETES MANAGEMENT ALGORITHM - 2017 EXECUTIVE SUMMARY.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11936-017-0552-4

Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11936-017-0552-4

Research into the effect Of SGLT2 inhibition on left ventricular remodelling in patients with heart failure and diabetes mellitus (REFORM) trial rationale and design.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11936-017-0552-4

Rationale and design of a randomized trial to test the safety and non-inferiority of canagliflozin in patients with diabetes with chronic heart failure: the CANDLE trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11936-017-0552-4

Ion-exchange resins for the treatment of hyperkalemia: are they safe and effective?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11936-017-0552-4

Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11936-017-0552-4

The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11936-017-0552-4

Eplerenone in Patients with Systolic Heart Failure and Mild Symptoms

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11936-017-0552-4

Potassium-Binding Agents to Facilitate Renin-Angiotensin-Aldosterone System Inhibitor Therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11936-017-0552-4

Treatment with patiromer decreases aldosterone in patients with chronic kidney disease and hyperkalemia on renin-angiotensin system inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11936-017-0552-4

A phase 2 study on the treatment of hyperkalemia in patients with chronic kidney disease suggests that the selective potassium trap, ZS-9, is safe and efficient

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11936-017-0552-4

Chronic Oral Study of Myosin Activation to Increase Contractility in Heart Failure (COSMIC-HF): a phase 2, pharmacokinetic, randomised, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11936-017-0552-4

What can we learn from RELAX-AHF compared to previous AHF trials and what does the future hold?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11936-017-0552-4

Serelaxin, recombinant human relaxin-2, for treatment of acute heart failure (RELAX-AHF): a randomised, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11936-017-0552-4

Relaxin for the treatment of patients with acute heart failure (Pre-RELAX-AHF): a multicentre, randomised, placebo-controlled, parallel-group, dose-finding phase IIb study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11936-017-0552-4

2013 ACCF/AHA Guideline for the Management of Heart Failure: Executive Summary

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11936-017-0552-4

2016 ACC/AHA/HFSA Focused Update on New Pharmacological Therapy for Heart Failure: An Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11936-017-0552-4

Potassium-Binding Agents for the Clinical Management of Hyperkalemia

21 January 2018

1 reference

12 December 2020

Repeated hospitalizations predict mortality in the community population with heart failure

1 reference

12 December 2020

Long-term prognostic value of resting heart rate in patients with suspected or proven coronary artery disease

1 reference

12 December 2020

2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines

1 reference

12 December 2020

Heart rate at baseline influences the effect of ivabradine on cardiovascular outcomes in chronic heart failure: analysis from the SHIFT study

1 reference

12 December 2020

Critical Questions about PARADIGM-HF and the Future

1 reference

12 December 2020

Glucose-lowering drugs or strategies and cardiovascular outcomes in patients with or at risk for type 2 diabetes: a meta-analysis of randomised controlled trials

1 reference

12 December 2020

FDA approves patiromer for nonemergent hyperkalemia

1 reference

12 December 2020

Euglycemic Diabetic Ketoacidosis: A Predictable, Detectable, and Preventable Safety Concern With SGLT2 Inhibitors

1 reference

12 December 2020

10.1007/S11936-017-0552-4

Identifiers

DOI

1 reference

11 September 2017

1 reference